Featured Publications
Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.
DiGiovanna MP, Stern DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Research 1995, 55: 1946-55. PMID: 7728765.Peer-Reviewed Original ResearchConceptsHuman breast tumorsBreast tumorsPrimary human breast tumorsPoor patient prognosisSubset of tumorsEpidermal growth factor receptorGrowth factor receptorPatient prognosisImmunohistochemical stainingNeu/ErbBTumor samplesTumorsMonoclonal antibodiesHuman tumorsFactor receptorRelated receptorsReceptorsP185Polyclonal antibodiesAntibodiesErbBRelated epidermal growth factor receptorSubsetTyrosine phosphoproteinsPrognosisEGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
Stern DF, Kamps MP. EGF‐stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. The EMBO Journal 1988, 7: 995-1001. PMID: 3261240, PMCID: PMC454426, DOI: 10.1002/j.1460-2075.1988.tb02906.x.Peer-Reviewed Original ResearchConceptsEGF-stimulated tyrosine phosphorylationTyrosine phosphorylationEGF receptorKinase activityReceptor-like proteinEGF receptor kinaseIntrinsic kinase activityRat-1 cellsTyrosine kinase activityEpidermal growth factor receptorReceptor kinaseGrowth factor receptorIncubation of cellsPhosphorylationEGFNeu/Factor receptorReceptor interactionSimilar kineticsGrowth factorP185ProteinP185neuReceptorsCells
2005
Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer
Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. Cancer Investigation 2005, 23: 483-487. PMID: 16203655, DOI: 10.1080/07357900500201301.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSingle-agent taxane therapyTaxane therapyP-HER2Clinical benefitBreast cancerClinical resistanceSingle-agent taxane chemotherapyUnique predictive informationChi-squared analysisTaxane chemotherapyClinical outcomesClinical progressionTaxane monotherapyHER2 statusClinical trialsPhosphorylated HER2Tumor specimensFunctional assessmentHER2TherapyMonoclonal antibodiesImmunohistochemistrySquared analysisProgression
2000
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
Stern D. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Research 2000, 2: 176. PMID: 11250707, PMCID: PMC138772, DOI: 10.1186/bcr51.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBiomarkersBreast NeoplasmsEpidermal Growth FactorErbB ReceptorsFemaleGene AmplificationGene Expression Regulation, DevelopmentalGene Expression Regulation, NeoplasticGenes, erbBHumansProtein-Tyrosine KinasesReceptor, ErbB-2Signal TransductionTranscriptional ActivationTransforming Growth FactorsTrastuzumabConceptsBreast cancerErbB family receptor tyrosine kinasesReceptor tyrosine kinasesHER2/neuTyrosine kinaseEpidermal growth factor receptorGrowth factor receptorClinical trialsSteroid receptorsTherapeutic antibodiesErbB-2Factor receptorReceptorsCancerPhysiological regulatorSignificant subsetFamily membersKinaseOptimal useNeuHormoneTrialsAntibodiesHerceptin
1996
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
DiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.Peer-Reviewed Original ResearchConceptsHER-2/neuPrognostic indicatorBreast carcinomaInvasive breast carcinomaHER-2/ neuHuman breast tumorsFunctional assaysHuman breast carcinomaClinicopathological characteristicsPoor prognosisInvasive human breast tumoursLarge seriesBreast tumorsNeuMonoclonal antibodiesCarcinomaTumorsAntibodiesDifferent reportsOverexpressionReportAssaysPrognosis
1991
TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro.
Cao H, Decker S, Stern DF. TPA inhibits the tyrosine kinase activity of the neu protein in vivo and in vitro. Oncogene 1991, 6: 705-11. PMID: 1675782.Peer-Reviewed Original ResearchConceptsImmune complex kinase assayReceptor-like proteinTyrosine kinase activityProtein kinase CThreonine phosphorylationThreonine residuesTransmembrane domainKinase assaysTyrosine phosphorylationKinase activityAntiphosphotyrosine antibodyIncubation of cellsKinase CPhosphorylationPoint mutationsProteinNeu/Neu proteinLabeling experimentsSerineP185PhosphotyrosineTPAOncogenicMutations
1990
The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.
Connelly PA, Stern DF. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Proceedings Of The National Academy Of Sciences Of The United States Of America 1990, 87: 6054-6057. PMID: 1974718, PMCID: PMC54470, DOI: 10.1073/pnas.87.16.6054.Peer-Reviewed Original Research
1987
Construction of a Novel Oncogene Based on Synthetic Sequences Encoding Epidermal Growth Factor
Stern DF, Hare DL, Cecchini MA, Weinberg RA. Construction of a Novel Oncogene Based on Synthetic Sequences Encoding Epidermal Growth Factor. Science 1987, 235: 321-324. PMID: 3492043, DOI: 10.1126/science.3492043.Peer-Reviewed Original Research
1986
Development of monoclonal antibodies reactive with the product of the neu oncogene.
Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Development of monoclonal antibodies reactive with the product of the neu oncogene. Symposium On Fundamental Cancer Research 1986, 38: 277-89. PMID: 3749645.Peer-Reviewed Original Research
1985
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
Drebin J, Link V, Stern D, Weinberg R, Greene M. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985, 41: 695-706. PMID: 2860972, DOI: 10.1016/s0092-8674(85)80050-7.Peer-Reviewed Original ResearchConceptsNIH 3T3 cellsAnchorage-independent growthAnti-p185 monoclonal antibodiesColony formationSoft agar colony formationAgar colony formationOncogene protein productGene productsNontransformed phenotypeProtein productsAntibody treatmentRas oncogeneDNA transfectionMonoclonal antibodiesNeu gene productSoft agarOncogenePhenotypeCellsP185P185 levelsNeuroblastoma linesUnrelated specificityControl antibodyNeu oncogene
1984
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene
Drebin J, Stern D, Link V, Weinberg R, Greene M. Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature 1984, 312: 545-548. PMID: 6504162, DOI: 10.1038/312545a0.Peer-Reviewed Original ResearchConceptsNIH 3T3 cellsCell surface antigensCellular oncogenesAnimal cancer cellsNormal NIH 3T3 cellsMonoclonal antibodiesTumor-associated antigensVariety of antigensRelative molecular massCell surface determinantsNon-malignant cellsGenetic elementsDifferent histological originDNA transfectantsDNA transfectionMolecular massNeoplastic processAntibody reactivityNeoplastic cellsMalignant cellsHistological originAntigenIdentical antigensOncogeneCancer cells